AU2001228638A1 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
AU2001228638A1
AU2001228638A1 AU2001228638A AU2863801A AU2001228638A1 AU 2001228638 A1 AU2001228638 A1 AU 2001228638A1 AU 2001228638 A AU2001228638 A AU 2001228638A AU 2863801 A AU2863801 A AU 2863801A AU 2001228638 A1 AU2001228638 A1 AU 2001228638A1
Authority
AU
Australia
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001228638A
Inventor
Frederic Henri Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001228638A1 publication Critical patent/AU2001228638A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
AU2001228638A 2000-01-28 2001-01-24 Chemical compounds Abandoned AU2001228638A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00400228 2000-01-28
EP00400228 2000-01-28
PCT/GB2001/000245 WO2001055116A2 (en) 2000-01-28 2001-01-24 Quinoline derivatives and their use as aurora 2 kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2001228638A1 true AU2001228638A1 (en) 2001-08-07

Family

ID=8173521

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001228638A Abandoned AU2001228638A1 (en) 2000-01-28 2001-01-24 Chemical compounds

Country Status (5)

Country Link
US (1) US6977259B2 (en)
EP (1) EP1294709A2 (en)
JP (1) JP2003520855A (en)
AU (1) AU2001228638A1 (en)
WO (1) WO2001055116A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE341545T1 (en) 2001-07-16 2006-10-15 Astrazeneca Ab QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7560558B2 (en) * 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
EP2609919A3 (en) * 2003-09-26 2014-02-26 Exelixis, Inc. c-Met modulators and methods of use
AU2013204031B2 (en) * 2003-09-26 2016-10-27 Exelixis, Inc. c-Met modulators and methods of use
JP2007514759A (en) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
WO2005070890A2 (en) 2004-01-16 2005-08-04 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
JP2007533753A (en) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド Indole derivatives and their use as kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
AR050948A1 (en) 2004-09-24 2006-12-06 Hoffmann La Roche DERIVATIVES OF FTALAZINONA; ITS OBTAINING AND ITS USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
BRPI0516093A (en) 2004-10-12 2008-08-19 Astrazeneca Ab quinazoline derivative, process for preparing it, pharmaceutical composition, use of a quinazoline derivative, and method for treating cell proliferative disorders in a warm-blooded animal
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
JP2008535876A (en) 2005-04-14 2008-09-04 エフ．ホフマン−ラ ロシュ アーゲー Aminopyrazole derivatives, their production and use as pharmaceutical formulations.
GB0509224D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007099323A2 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
UY30183A1 (en) 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
EP1994028A1 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives for treating cancer
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
TWI577664B (en) 2009-01-16 2017-04-11 艾克塞里克斯公司 Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, pharmaceutical composition comprising the same and use thereof
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CA2829131C (en) 2011-03-04 2018-11-20 Glaxosmithkline Intellectual Property (No.2) Limited Amino-quinolines as kinase inhibitors
TWI547494B (en) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 Amino quinazolines as kinase inhibitors
CN103304489B (en) * 2012-03-16 2015-03-11 中国农业科学院兰州畜牧与兽药研究所 Pyrimidine benzamide compound and preparation and application thereof
AR092530A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc AMINO-QUINOLINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND FOR THE PREPARATION OF A MEDICINAL PRODUCT
AR092529A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc AMINOQUINAZOLINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOSITE FOR THE PREPARATION OF A MEDICINAL PRODUCT
KR20150118152A (en) 2013-02-21 2015-10-21 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Quinazolines as kinase inhibitors
CN111808098B (en) * 2020-06-29 2021-08-24 Vtv治疗有限责任公司 Quinoline derivatives, pharmaceutically acceptable salts thereof, and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3121720A (en) * 1964-02-18 I-substituted tetrahydro isoquevolines
FR2543E (en) * 1901-09-23 1904-05-06 Jules Heizmann Apparatus or part of an apparatus for the exchange or transmission of heat between gaseous or liquid fluids and other substances
US3075981A (en) * 1958-04-03 1963-01-29 Sterling Drug Inc 1-[aromatic-(lower-alkyl)]-4-(aromaticimino)-1, 4-dihydroquinolines and their preparation
ES299510A3 (en) * 1964-04-28 1964-06-16 Ind Iberica Quimico Farmaceuti A procedure for the obtaining of (pyridil-2 ') amino-4 chlorine-7-quinolein (Machine-translation by Google Translate, not legally binding)
ES299684A3 (en) * 1964-04-29 1964-07-01 Ind Iberica Quimico Farmaceuti A procedure for the obtaining of (methyl-4'-pyridil-2 ') amino-4-chlorine-7-quinolein (Machine-translation by Google Translate, not legally binding)
FR2154326A1 (en) * 1971-09-30 1973-05-11 Crt (7' or 8' chloro-4-quinolinyl)-2-amino-nicotinic acid derivs - - analgesic,antiinflammatory
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
JP2994165B2 (en) * 1992-06-26 1999-12-27 ゼネカ・リミテッド Quinazoline derivative, method for producing the same, and pharmaceutical preparation containing the quinazoline derivative for obtaining anticancer activity
JPH0649062A (en) * 1992-07-31 1994-02-22 Mitsui Toatsu Chem Inc Pyrimidinylamino-or triazinylaminoquinoline derivative and its production and agricultural and horticultural germicide containing the same as active ingredient
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
WO1997017329A1 (en) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
PL355667A1 (en) 1999-11-29 2004-05-04 Aventis Pharma S.A. Arylamine derivatives and their use as anti-telomerase agent

Also Published As

Publication number Publication date
WO2001055116A2 (en) 2001-08-02
EP1294709A2 (en) 2003-03-26
US20030105129A1 (en) 2003-06-05
US6977259B2 (en) 2005-12-20
WO2001055116A3 (en) 2001-12-27
JP2003520855A (en) 2003-07-08

Similar Documents

Publication Publication Date Title
AU2002222228A1 (en) Chemical compounds
AU2001284584A1 (en) Chemical compounds
AU2001262886A1 (en) Chemical compounds
AU2001228638A1 (en) Chemical compounds
EG26979A (en) Chemical compounds
AU4699701A (en) Chemical compounds
GB0002032D0 (en) Chemical compounds
AU2002225730A1 (en) Compounds
GB0003224D0 (en) Chemical compounds
AU9572301A (en) Chemical compounds
AUPQ968300A0 (en) Chemical methods
AU7993801A (en) Chemical compounds
AUPQ661800A0 (en) Insulin-potentiating compounds
AU2002366440A1 (en) Chemical compounds
GB0002034D0 (en) Chemical compounds
GB0002033D0 (en) Chemical compounds
AU2002225724A1 (en) Motilide compounds
GB0001346D0 (en) Chemical compounds
GB0000626D0 (en) Chemical compounds
AU2002217285A1 (en) Compounds
GB0001348D0 (en) Chemical compounds
GB0002040D0 (en) Chemical compounds
AU2002216043A1 (en) Compounds
GB0002031D0 (en) Chemical compounds
GB0002036D0 (en) Chemical compounds